MTS109 in Patients With Refractory Autoimmune Diseases — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

MTS109 in Patients With Refractory Autoimmune Diseases — Stella

Home/Systemic Lupus Erythematosus/

View on ClinicalTrials.gov

Recruiting

Back to Systemic Lupus Erythematosus trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Shanghai ChangZheng Hospital, Shanghai, Shanghai Municipality

Key details

Phase

Very early testing

Sponsor

Shanghai Changzheng Hospital

Collaborators

Metis Techbio

Enrollment target

~15 participants

Started

March 2026

Primary completion

April 2028

Age range

18 Years – 65 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.